Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Targovax ASA ( (GB:0RIS) ) just unveiled an update.
Circio Holding ASA, a biotechnology company specializing in circular RNA expression systems for gene and cell therapy, has developed its proprietary circVec platform to significantly extend RNA half-life and boost protein production in next-generation therapeutics. The technology is positioned as a potential new standard for gene expression across multiple treatment modalities, including chronic disease and advanced cell-based interventions.
The company has entered a research collaboration with Tokyo-based United Immunity to explore in vivo CAR-macrophage therapies by combining circVec with United’s P-LNP delivery technology targeting myeloid cells. The partners aim to assess whether circVec can prolong gene expression in these immune cells, potentially creating a differentiated joint platform for novel CAR-M treatments in oncology, fibrosis and autoimmune disorders, which could enhance Circio’s standing in the rapidly evolving in vivo cell therapy field.
More about Targovax ASA
Circio Holding ASA is a Norway-based biotechnology company focused on developing circular RNA expression technology for advanced gene and cell therapies. Its proprietary circVec platform is a modular circRNA vector system designed for next-generation RNA, DNA and viral therapeutics, with applications spanning genetic medicine, cell therapy and chronic diseases, and has demonstrated markedly prolonged RNA stability and higher protein expression versus conventional mRNA systems.
Average Trading Volume: 7,875,613
Current Market Cap: NOK1.24B
For an in-depth examination of 0RIS stock, go to TipRanks’ Overview page.